



68811-A.ST25
SEQUENCE LISTING

<110> Cohen-Vered, et al., Sharon

<120> PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

<130> 2609/68811-A

<140> 10/758,397

<141> 2004-01-14

<160> 18

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 1

Thr Gly Tyr Tyr Met Gln Trp Val Lys Gln Ser Pro Glu Lys Ser Leu
1 5 10 15

Glu Trp Ile Gly
20

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

68811-A.ST25

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 2

Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys
1 5 10 15

Ala Lys Ala Thr
20

<210> 3

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 3

Tyr Tyr Cys Ala Arg Phe Leu Trp Glu Pro Tyr Ala Met Asp Tyr Trp
1 5 10 15

Gly Gln Gly Ser
20

<210> 4

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 4

Gly Tyr Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu
1 5 10 15

Trp Ile Gly

<210> 5

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 5

Tyr Tyr Cys Ala Arg Ser Gly Arg Tyr Gly Asn Tyr Trp Gly Gln Thr
1 5 10 15

Leu

<210> 6

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 6

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu
1 5 10 15

Trp Ile Gly

<210> 7

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

68811-A.ST25

<400> 7

Tyr Tyr Cys Ala Arg Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp
1 5 10 15

Tyr Tyr Gly Met Asp Val
20

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 8

Phe Ser Gly Tyr Tyr Trp Ser
1 5

<210> 9

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 9

Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Lys Thr Ser Leu Lys Ser
1 5 10 15

<210> 10

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 10

Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp Tyr Tyr Tyr Gly Met
 1 5 10 15

Asp Val

<210> 11

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X= Met, Ala or Val

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X= Gln, Asp, Glu or Arg

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X= Trp or Ala

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X= Val or Ser

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X= Lys, Glu or Ala

<400> 11

Thr	Gly	Tyr	Tyr	Xaa	Xaa	Xaa	Xaa	Xaa	Gln	Ser	Pro	Glu	Lys	Ser	Leu
1				5					10					15	

Glu	Trp	Ile	Gly
			20

<210> 12

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X= Thr, Val or Ala

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X= Thr, Val or Ala

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> X= Tyr or Phe

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> X= Asn or Asp

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X =Gln or Glu

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> X= Lys or Glu

<220>

<221> MISC_FEATURE

<222> (15)..(15)

<223> X= Phe or Tyr

<400> 12

Glu	Ile	Asn	Pro	Ser	Thr	Gly	Gly	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Lys
1				5				10					15	

Ala	Lys	Ala	Thr
			20

<210> 13

<211> 20

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X= Phe, Thr or Gly

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X= Leu, Ala or Ser

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X= Trp or Ala

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X= Glu or Lys

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X= Met or Ala

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> X= Asp, Lys or Ser

<400> 13

Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Xaa Pro Tyr Ala Xaa Xaa Tyr Trp
 1 5 10 15

Gly Gln Gly Ser
 20

<210> 14

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X= Met or Ala

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X= Asn, Asp or Arg

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X= Trp or Ala

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X= Val or Ser

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X= Lys or Glu

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X= Gln or Ala

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X= Lys or Glu

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> X= Ser or Ala

<400> 14

Gly	Tyr	Asn	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Ser	His	Gly	Xaa	Xaa	Leu	Glu
1				5					10					15	

Trp Ile Gly

<210> 15

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X= Ser or Phe

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X= Gly or Ala

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X= Arg, Ala or Glu

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> X= Asn or Asp

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> X= Tyr or Phe

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X= Trp, His or Ala

<400> 15

Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Tyr Gly Xaa Xaa Xaa Gly Gln Thr
 1 5 10 15

Leu

<210> 16

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide basedon CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X= Gly or Thr

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X= Arg or Lys

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X= Pro or Ser

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> X= Gly or Glu

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X= Lys or Asp

<220>

<221> MISC_FEATURE

<222> (15)..(15)

<223> X= Glu, Leu or Ser

<400> 16

Xaa Tyr Tyr Trp Ser Trp Ile Xaa Gln Xaa Pro Xaa Xaa Gly Xaa Glu
 1 5 10 15

Trp Ile Gly

<210> 17

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide basedon CDR of mouse autoantibody

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X= Gly or Phe

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> X= Arg or Ala

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X= Gly or Ala

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> X= Gly or Ala

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> X= Trp or Ala

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> X= Asn or Ala

<220>

<221> MISC_FEATURE

<222> (18)..(18)

<223> X= Tyr or Trp

<220>

<221> MISC_FEATURE

<222> (20)..(20)

<223> X= Met or Gln

<400> 17

68811-A.ST25

Tyr Tyr Cys Ala Arg Xaa Leu Leu Xaa Xaa Xaa Xaa Xaa Asp Val Asp
 1 5 10 15

Tyr Xaa Gly Xaa Asp Val
 20

<210> 18

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide based on the complementarity-determining region
 1 of human anti-dsDNA mAb denoted 16/6 Id

<400> 18

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu
 1 5 10 15

Trp Ile Gly